We are live on ! Find out more
SVCM

Saturn V Capital Management Portfolio holdings

AUM $552M
1-Year Est. Return 551.78%
This Fund
S&P 500
This Quarter Est. Return
+6.25%
1 Year Est. Return
+551.78%
3 Year Est. Return
+970.54%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$239M
AUM Growth
+$58.6M
Cap. Flow
+$60M
Cap. Flow %
25.13%
Top 10 Hldgs %
71.73%
Holding
24
New
4
Increased
14
Reduced
2
Closed
4

Top Buys

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$18.7M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$12M
3
ANAB icon
AnaptysBio
ANAB
+$11M
4
COGT icon
Cogent Biosciences
COGT
+$7.5M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$7.28M

Top Sells

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$20.2M
2
APLS
Apellis Pharmaceuticals
APLS
+$9.78M
3
SAGE
Sage Therapeutics
SAGE
+$3.32M
4
CBAY
Cymabay Therapeutics
CBAY
+$840K
5
MORF
Morphic Holding, Inc. Common Stock
MORF
+$820K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRNX icon
1
Crinetics Pharmaceuticals
CRNX
$8.88B
$33.5M 14.02%
1,126,579
+187,902
+20% +$3.87M
KALV
2
DELISTED
KalVista Pharmaceuticals
KALV
$17.4M 7.3%
1,810,246
+397,910
+28% +$4.07M
COGT icon
3
Cogent Biosciences
COGT
$6.54B
$17.3M 7.25%
1,775,415
+632,047
+55% +$7.5M
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
$16.8M 7.02%
1,124,459
-63,342
-5% -$840K
BIIB icon
5
Biogen
BIIB
$29.5B
$16.6M 6.96%
64,676
+23,629
+58% +$6.32M
AMLX icon
6
Amylyx Pharmaceuticals
AMLX
$1.94B
$16.2M 6.79%
+886,143
New +$18.7M
CYTK icon
7
Cytokinetics
CYTK
$10.7B
$14.6M 6.11%
495,168
+88,943
+22% +$2.96M
SRPT icon
8
Sarepta Therapeutics
SRPT
$1.78B
$14.4M 6.01%
118,401
+64,406
+119% +$7.28M
HZNP
9
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$12.8M 5.38%
111,045
+11,550
+12% +$1.24M
SNDX icon
10
Syndax Pharmaceuticals
SNDX
$1.98B
$11.7M 4.91%
807,969
+634,252
+365% +$12M
ITOS
11
DELISTED
iTeos Therapeutics
ITOS
$10.9M 4.56%
994,756
+358,598
+56% +$4.59M
ASND icon
12
Ascendis Pharma A/S
ASND
$16.5B
$10.5M 4.41%
112,473
+34,031
+43% +$3.18M
ANAB icon
13
AnaptysBio
ANAB
$1.49B
$10.4M 4.34%
+577,101
New +$11M
BMRN icon
14
BioMarin Pharmaceuticals
BMRN
$11.4B
$9.7M 4.06%
109,685
+17,059
+18% +$1.52M
ATXS
15
DELISTED
Astria Therapeutics
ATXS
$9.09M 3.81%
1,219,093
+581,236
+91% +$4.96M
BCRX icon
16
BioCryst Pharmaceuticals
BCRX
$2.32B
$6.96M 2.91%
982,458
+27,602
+3% +$198K
ARGX icon
17
argenx
ARGX
$52.9B
$4.95M 2.07%
10,074
+5,993
+147% +$2.93M
MORF
18
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$3.13M 1.31%
136,743
-15,617
-10% -$820K
JSPR icon
19
Jasper Therapeutics
JSPR
$27.1M
$971K 0.41%
+138,702
New +$1.69M
MRUS
20
DELISTED
Merus
MRUS
$945K 0.4%
+40,066
New +$972K
APLS
21
DELISTED
Apellis Pharmaceuticals
APLS
– –
-107,406
Closed -$9.78M
SAGE
22
DELISTED
Sage Therapeutics
SAGE
– –
-70,559
Closed -$3.32M
SCLX icon
23
Scilex Holding
SCLX
$53.7M
– –
-297
Closed -$57.9K
KDNY
24
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-524,811
Closed -$20.2M

Similar funds

LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
FWM
FFT Wealth Management Philadelphia, Pennsylvania $552M AUM 16.82% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $552M AUM 26% 1-Year Est. Return
DCM
Davidson Capital Management Corpus Christi, Texas $552M AUM 22.73% 1-Year Est. Return
TC
Triata Capital Hong Kong $552M AUM 2.89% 1-Year Est. Return
BT
Brandywine Trust Hockessin, Delaware $552M AUM 5.23% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return
IQI
Integrated Quantitative Investments Bellevue, Washington $551M AUM 45.27% 1-Year Est. Return

Saturn V Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Saturn V Capital Management held 24 positions worth $239M, up 33% from $180M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Saturn V Capital Management deployed $60M of net new capital in Q3 2023, opening 4 new positions and adding to 14 existing holdings. Its largest new stake was Amylyx Pharmaceuticals: 886,143 shares worth $16.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Cymabay Therapeutics, an estimated $840K trimmed.

  • Saturn V Capital Management's largest Q3 2023 buy was Amylyx Pharmaceuticals: 886,143 shares worth $16.2M.
  • Saturn V Capital Management added most to Syndax Pharmaceuticals in Q3 2023, an estimated $12M increase.
  • Saturn V Capital Management's biggest Q3 2023 reduction was Cymabay Therapeutics, cutting an estimated $840K.
  • Saturn V Capital Management fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $20.2M.
  • Saturn V Capital Management's ten largest holdings make up 72% of its $239M portfolio in Q3 2023.
  • Saturn V Capital Management opened 4 new positions and closed 4 in Q3 2023.
  • Saturn V Capital Management's portfolio value rose 33% quarter-over-quarter to $239M.

Based on Saturn V Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.